<DOC>
	<DOCNO>NCT00972322</DOCNO>
	<brief_summary>This study ass safety , tolerability , pharmacokinetics , glucose lower activity MK-8245 participant type 2 diabetes . The primary hypothesis study 4 week treatment , MK-8245 produce great reduction 24 hour weight mean glucose ( WMG ) baseline placebo .</brief_summary>
	<brief_title>Pharmacokinetics Pharmacodynamics MK-8245 Participants With Type 2 Diabetes ( MK-8245-012 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Subject diagnosis type 2 diabetes treat diet exercise alone , single oral antihyperglycemic agent combination two oral antihyperglycemic agent Subject willing follow weightmaintaining diet exercise program study Subject nonsmoker willing limit smoke 10 cigarette per day clinical research unit Subject history stroke , chronic seizure , major neurological disorder Subject history cancer , except certain skin cervical cancer cancer successfully treat 10 year prior screen Subject history type 1 diabetes Subject use contact lens within last 6 month Subject use lipidlowering therapy last 3 month , except statin , Zetia , Vytorin Subject 3 alcoholic beverage per day Subject 6 serving caffeine day Subject participate previous MK8245 study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>